Full story
by Dr. Joseph Mercola
October 26, 2005
mercola.com
We bring to the attention of Global Research readers this important commentary by Dr.Joseph Mercola.
The fundamental issue is who owns the intellectual property rights over Tamiflu. The media reports suggest that the Swiss pharmaceutical company Roche will make billions.
While the drug is produced by Roche, it was developed by Gilead Sciences Inc.which owns the intellectual property rights. Gilead, which has maintained a low profile, has outsourced the production to Roche.
Donald Rumsfeld was appointed Chairman of Gilead Sciences, Inc. in 1997, a position which he held in the years prior to becoming Secretary of Defense.in the Bush adminstration. Rumsfeld had been on the Board of Directors from the establishment of Gilead in 1987.
As confirmed in a company press statement in 1997, Donald H. Rumsfeld assumed the position of Chairman, of GILEAD: :
"Gilead is fortunate to have had Don Rumsfeld as a stalwart board member since the company's earliest days, and we are very pleased that he has accepted the Chairmanship," Dr. Riordan said. "He has played an important role in helping to build and steer the company. His broad experience in leadership positions in both industry and government will serve us well as Gilead continues to build its commercial presence."
According to company statement: Gilead Science Inc "has been active in the development of inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV"
"The Company's research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and genetic code blockers for cancer and other diseases. Gilead's expertise in each of these areas has also resulted in the discovery and development of non-nucleotide product candidates, including neuraminidase inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV"
Also find below an article published in the SF Chronicle, which points to the relationship between GILEAD and Roche in relation to the Rights over Tami Flu.
by Dr. Joseph Mercola
October 26, 2005
mercola.com
We bring to the attention of Global Research readers this important commentary by Dr.Joseph Mercola.
The fundamental issue is who owns the intellectual property rights over Tamiflu. The media reports suggest that the Swiss pharmaceutical company Roche will make billions.
While the drug is produced by Roche, it was developed by Gilead Sciences Inc.which owns the intellectual property rights. Gilead, which has maintained a low profile, has outsourced the production to Roche.
Donald Rumsfeld was appointed Chairman of Gilead Sciences, Inc. in 1997, a position which he held in the years prior to becoming Secretary of Defense.in the Bush adminstration. Rumsfeld had been on the Board of Directors from the establishment of Gilead in 1987.
As confirmed in a company press statement in 1997, Donald H. Rumsfeld assumed the position of Chairman, of GILEAD: :
"Gilead is fortunate to have had Don Rumsfeld as a stalwart board member since the company's earliest days, and we are very pleased that he has accepted the Chairmanship," Dr. Riordan said. "He has played an important role in helping to build and steer the company. His broad experience in leadership positions in both industry and government will serve us well as Gilead continues to build its commercial presence."
According to company statement: Gilead Science Inc "has been active in the development of inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV"
"The Company's research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and genetic code blockers for cancer and other diseases. Gilead's expertise in each of these areas has also resulted in the discovery and development of non-nucleotide product candidates, including neuraminidase inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV"
Also find below an article published in the SF Chronicle, which points to the relationship between GILEAD and Roche in relation to the Rights over Tami Flu.
